drugset / Trial / NCT05901935
DP303c in Patients With HER2-positive Advanced Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a study of DP303c in patients with HER2-positive advanced breast cancer.
Timeline
- Start
- 2023-07
- Primary completion
- 2026-01
- Completion
- 2028-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | TRASTUZUMAB ENVEDOTIN | Monoclonal antibody | 3 mg/kg | — |
| Comparator | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Comparator | Vinorelbine | Small molecule | 25 mg/m2 | Intravenous |